-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading Up 3.4%
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading Up 3.4%
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) shares rose 3.4% during trading on Monday . The stock traded as high as $1.86 and last traded at $1.85. Approximately 3,706 shares were traded during trading, a decline of 66% from the average daily volume of 10,945 shares. The stock had previously closed at $1.79.
Analyst Ratings Changes
Separately, LADENBURG THALM/SH SH began coverage on Anebulo Pharmaceuticals in a research note on Wednesday, July 27th. They issued a "buy" rating and a $6.00 price target for the company.
Get Anebulo Pharmaceuticals alerts:Anebulo Pharmaceuticals Price Performance
The stock's 50-day moving average price is $3.07 and its 200-day moving average price is $3.55.
Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Rating) last issued its quarterly earnings results on Friday, September 9th. The company reported ($0.10) EPS for the quarter. Equities research analysts forecast that Anebulo Pharmaceuticals, Inc. will post -0.51 earnings per share for the current fiscal year.Institutional Investors Weigh In On Anebulo Pharmaceuticals
An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. LVW Advisors LLC acquired a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 700,000 shares of the company's stock, valued at approximately $3,640,000. LVW Advisors LLC owned 3.00% of Anebulo Pharmaceuticals as of its most recent SEC filing. 20.04% of the stock is owned by institutional investors and hedge funds.
About Anebulo Pharmaceuticals
(Get Rating)
Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose.
Featured Articles
- Get a free copy of the StockNews.com research report on Anebulo Pharmaceuticals (ANEB)
- Kimberly-Clark Products Post Weak Quarter Despite Raising Prices
- Why is Kraft Heinz Stock Moving Higher? It's a Great Bargain
- Is This The Bottom For Canopy Growth Corporation?
- Solar-Industry Small Cap Array Set For Big EPS Growth In 2023
- Unity Software is the Other Video Game Engine To Watch
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) shares rose 3.4% during trading on Monday . The stock traded as high as $1.86 and last traded at $1.85. Approximately 3,706 shares were traded during trading, a decline of 66% from the average daily volume of 10,945 shares. The stock had previously closed at $1.79.
纳斯达克(AneBulo PharmPharmticals，Inc.)股价周一上涨3.4%。该股一度涨至1.86美元，最后报1.85美元。当日成交量约为3,706股，较10,945股的日均成交量下降66%。该股此前收盘价为1.79美元。
Analyst Ratings Changes
分析师评级发生变化
Separately, LADENBURG THALM/SH SH began coverage on Anebulo Pharmaceuticals in a research note on Wednesday, July 27th. They issued a "buy" rating and a $6.00 price target for the company.
另外，拉登堡THALM/SH SH在7月27日星期三的一份研究报告中开始报道AneBulo制药公司。他们对该公司的评级为“买入”，目标价为6美元。
Anebulo Pharmaceuticals Price Performance
AneBulo制药公司的价格表现
The stock's 50-day moving average price is $3.07 and its 200-day moving average price is $3.55.
该股的50日移动均线价格为3.07美元，200日移动均线价格为3.55美元。
Institutional Investors Weigh In On Anebulo Pharmaceuticals
机构投资者看好AneBulo制药公司
An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. LVW Advisors LLC acquired a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 700,000 shares of the company's stock, valued at approximately $3,640,000. LVW Advisors LLC owned 3.00% of Anebulo Pharmaceuticals as of its most recent SEC filing. 20.04% of the stock is owned by institutional investors and hedge funds.
一家机构投资者最近买入了AneBulo PharmPharmticals股票的新头寸。根据LVW Advisors LLC在第二季度收购了AneBulo PharmPharmticals，Inc.(纳斯达克代码：ANEB-GET Rating)的新股票头寸，该公司在最近提交给美国证券交易委员会的信息中称。该公司收购了70万股该公司股票，价值约3,640,000美元。截至最近提交给美国证券交易委员会的文件，LVW Advisors LLC拥有AneBulo PharmPharmticals 3.00%的股份。20.04%的股票由机构投资者和对冲基金持有。
About Anebulo Pharmaceuticals
关于AneBulo制药公司
(Get Rating)
(获取评级)
Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose.
AneBulo PharmPharmticals，Inc.是一家临床阶段的生物技术公司，致力于开发和商业化治疗急性大麻素中毒和药物成瘾的患者。它的主要候选产品是ANEB-001，这是一种治疗大麻类药物中毒和过量的小分子大麻受体拮抗剂。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Anebulo Pharmaceuticals (ANEB)
- Kimberly-Clark Products Post Weak Quarter Despite Raising Prices
- Why is Kraft Heinz Stock Moving Higher? It's a Great Bargain
- Is This The Bottom For Canopy Growth Corporation?
- Solar-Industry Small Cap Array Set For Big EPS Growth In 2023
- Unity Software is the Other Video Game Engine To Watch
- 免费获取StockNews.com关于AneBulo制药公司的研究报告(ANEB)
- 金佰利产品尽管提价，但季度业绩疲软
- 为什么卡夫亨氏的股票会走高？这是一笔很划算的交易
- 这是Canopy Growth公司的底部吗？
- 2023年太阳能行业小型帽阵列将迎来每股收益的大幅增长
- Unity Software是另一个值得关注的视频游戏引擎
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受AneBulo制药日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对AneBulo PharmPharmticals和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧